Vas-01 is under clinical development by VasGene Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vas-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vas-01 overview

Vas-01 (Recombinant fusion protein) is under development for the treatment of metastatic castration-resistant prostate cancer, Kaposi sarcoma and metastatic or recurrent solid tumors, metastatic urothelial carcinoma, non-small cell lung cancer, refractory bladder cancer, pancreatic cancer, colorectal cancer, head and neck cancer squamous cell carcinomas like hypopharyngeal carcinoma, laryngeal cancer, lip and oral cavity cancer, oropharyngeal carcinoma, malignant pleural mesothelioma, bile duct cancer (cholangiocarcinoma), gall bladder cancer and hepatocellular carcinoma. The drug is administered intravenously and intravesically. The recombinant fusion protein is composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and fused, at its C-terminus, to full-length human serum albumin (HSA).

The drug was also under development for relapsed or refractory myelodysplastic syndrome and acute myeloid leukemia.

VasGene Therapeutics overview

VasGene Therapeutics (VasGene) is a biotechnology company that discovers, develops and commercializes therapeutics based on the understanding of vascular biology and cancer biology. The company offers pipeline products such as soluble therapeutic proteins, therapeutic monoclonal antibodies, and anti-drug conjugates. VasGene’s products are used in the treatment of cancer, AMD, and diabetic eye. It markets its products through its network of distributors across the world. The company provides the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics. VasGene is headquartered in Los Angeles, California, the US.

For a complete picture of Vas-01’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.